VolitionRX Q2 EPS $(0.14) Beats $(0.15) Estimate, Sales $216.31K Miss $270.00K Estimate
Portfolio Pulse from vinayak@benzinga.com
VolitionRX reported Q2 losses of $(0.14) per share, beating the analyst consensus estimate of $(0.15) by 6.67%. However, the company's quarterly sales of $216.31K missed the analyst consensus estimate of $270.00K by 19.89%. This represents a 444.15% increase over sales of $39.75K the same period last year.
August 14, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VolitionRX's Q2 earnings per share beat estimates, but sales missed expectations. Sales have significantly increased compared to the same period last year.
VolitionRX's earnings per share beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. The significant YoY increase in sales could be seen as a positive sign of growth, potentially offsetting the negative impact of missing sales estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100